MRA-based aneurysm occlusion assessment in the early phase after flow diverter treatment: a multicenter retrospective study focusing on the impact of aneurysm diameter

基于磁共振血管造影(MRA)的动脉瘤闭塞评估在血流导向装置治疗早期阶段的应用:一项多中心回顾性研究,重点关注动脉瘤直径的影响

阅读:1

Abstract

BACKGROUND: Although it is well-known that most aneurysms occlude within 1 year after flow diverter (FD) treatment, the time course to occlusion, especially in the early period, has not been adequately studied. METHODS: This study included patients treated with FDs between April 2018 and December 2024 and underwent at least 3 months of imaging follow-up with MRA. The primary outcome was aneurysm occlusion without rupture during follow-up. Cumulative aneurysm occlusion rates were assessed using repetitive time-of-flight and ultrashort echo-time MRA. Predictors of aneurysm occlusion were analyzed with special interests to patient backgrounds, anatomical factors including aneurysm diameter, and procedural details. RESULTS: This study included 119 patients (male: female ratio, 15:104; mean age, 58 ± 14 years; average diameter, 10.8 mm). During the median follow-up of 12 months, the cumulative occlusion rates at 3, 6, and 12 months were 15%, 48%, and 79%, respectively. Receiver operating characteristic analysis identified the diameter threshold of 10.9 mm to best predict its occlusion, and aneurysms larger than this cutoff showed lower cumulative occlusion rates (P = 0.002 [log-rank test], hazard ratio 0.49 [P = 0.003]). In the multivariable Cox hazard model, an increase in aneurysm diameter (Hazard ratio 0.92, P = 0.002) was a preventive factor for aneurysm occlusion, whereas adjunctive coiling (Hazard ratio 2.05, P = 0.009) significantly promoted the occlusion rate. CONCLUSIONS: In postoperative follow-up using repetitive MRA, larger aneurysms exhibited the trend to occlude slower after FD treatment, whereas adjunctive coiling promoted the time course to aneurysm occlusion. Future prospective studies are warranted to investigate technical factors to further promote aneurysm occlusion. CLINICAL TRIAL NUMBER: UMIN000057450.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。